Status:

UNKNOWN

The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Fecal Incontinence

Lead Sponsor:

Seoul National University Hospital

Conditions:

Fecal Incontinence

Eligibility:

All Genders

19+ years

Phase:

PHASE2

PHASE3

Brief Summary

This clinical trial aims to assess the effectiveness of Ramosetron compared to Psyllium, a gold standard therapy, in patients with fecal incontinence. The primary questions it seeks to answer are: 1....

Eligibility Criteria

Inclusion

  • Patients diagnosed with fecal incontinence (patients with 2 or more symptoms of fecal incontinence per month for at least 3 months).
  • Patients who are able to understand and comply with this study.
  • Individuals who are agreeable to being on contraception for the duration of the study.

Exclusion

  • Patients who have difficulty swallowing medications
  • Patients with gastrointestinal deformities due to surgery
  • Patients with malabsorption
  • Patients with inflammatory bowel disease (IBD)
  • Patients undergoing treatment for cancer of the gastrointestinal tract
  • Patients who are allergic to the study drug
  • Patients with overflow incontinence and fecal impaction on rectal residual examination (DRE) or Bristol Stool Scale of 3 or less.
  • Patients taking medication for fecal incontinence within 1 month of study entry.
  • Pregnant or lactating women.
  • Patients with contraindications to any of the study drugs (i.e., intestinal obstruction, intestinal stones, acute abdomen, undiagnosed abdominal pain/nausea/vomiting, gastrointestinal stenosis and dysphagia, patients with megacolon syndrome, severe diabetes, etc.).
  • Patients taking an agent that is contraindicated in combination with either study drug.
  • Patients deemed by the investigator and staff to be unsuitable for participation in the study.

Key Trial Info

Start Date :

December 15 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 1 2024

Estimated Enrollment :

148 Patients enrolled

Trial Details

Trial ID

NCT06166615

Start Date

December 15 2023

End Date

November 1 2024

Last Update

December 12 2023

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Fecal Incontinence | DecenTrialz